Pfizer CoV-2 MPro Inhibitor
oral pan-coronavirus antiviral, rev. covalent Ph. III candidate for COVID-19 (300 mg BID) from SARS-CoV-1 inhibitor (WO2005113580) paxlovid (PF-07321332) Pfizer Worldwide Research
Molecules of the Month - 2021 Molecules of the Year Nominees
- Pfizer CoV-2 MPro Inhibitor
- Arvinas ER Chimeric Degrader
- Kronos CDK9 Inhibitor
- Merck PCSK9 Inhibitors
- Mirati KRASG12D Inhibitor
- Takeda EGFRex20 Inhibitor
- Lilly GLP Molecular Glue
- RevMed KRASG12C Tricomplex Inhibitor
- Genentech mPI3Kα Degrader
- H3Bio SF3b Splicing Modulator
- BioCryst Kallikrein Inhibitor
- Genentech ER Degrader
- Pfizer CoV-2 MPro Inhibitor
- Arvinas ER Chimeric Degrader
- Kronos CDK9 Inhibitor
- Merck PCSK9 Inhibitors
- Mirati KRASG12D Inhibitor
- Takeda EGFRex20 Inhibitor
- Lilly GLP Molecular Glue
- RevMed KRASG12C Tricomplex Inhibitor
- Genentech mPI3Kα Degrader
- H3Bio SF3b Splicing Modulator
- BioCryst Kallikrein Inhibitor
- Genentech ER Degrader